Welcome to our dedicated page for Kura Oncology SEC filings (Ticker: KURA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Kura Oncology, Inc. (Nasdaq: KURA) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, including current reports, financial updates and material agreements. As a biopharmaceutical company focused on precision medicines for cancer, Kura uses these filings to report significant events related to its lead menin inhibitor program, KOMZIFTI (ziftomenib), and its broader pipeline.
Recent Form 8-K filings describe key milestones such as full U.S. Food and Drug Administration approval of KOMZIFTI for adult patients with relapsed or refractory acute myeloid leukemia with a susceptible NPM1 mutation, clinical data from the pivotal KOMET-001 trial, and the wholesale acquisition cost for a one-month supply of KOMZIFTI. Other 8-Ks outline collaboration and co-promotion agreements with Kyowa Kirin, including terms under which Kura leads development, regulatory and commercial strategy in the United States while Kyowa Kirin leads efforts outside the United States.
Filings also cover financial results releases under Item 2.02, inducement equity plans and amendments, and milestone payments associated with the KOMET-017 Phase 3 registrational trials. These documents provide insight into Kura’s commercialization of KOMZIFTI, its clinical development plans for ziftomenib in newly diagnosed and relapsed or refractory AML, and its farnesyl transferase inhibitor programs.
On Stock Titan, investors can review KURA’s SEC filings alongside AI-powered summaries that highlight the main points of each document. This includes quick views of material events, collaboration structures, and key clinical or regulatory disclosures, helping users navigate detailed 8-Ks and related exhibits without reading every line.
Kura Oncology (KURA) Form 144 notice reports a proposed sale of 36,615 shares of common stock, to be executed on 09/29/2025 on NASDAQ through Morgan Stanley Smith Barney LLC. The shares were acquired as PSUs from the issuer on 09/27/2025 and carry an aggregate market value of $331,365.75 based on the filing. The filing states there were no securities sold by the reporting person in the prior three months.
The notice includes the standard representation that the seller does not possess any undisclosed material adverse information about the issuer and references Rule 10b5-1 plan disclosure as applicable. No other financial results, holdings, or related-party details are provided in the document.
Form 144 notice summary: This filing reports a proposed sale of 4,541 shares of Kura Oncology common stock on NASDAQ through Morgan Stanley Smith Barney LLC on 09/29/2025. The shares were acquired as PSUs from the issuer on 09/27/2025. The filing lists an aggregate market value of $41,096.05 based on reported figures and shows 87,015,518 shares outstanding. The filer reports no securities sold in the past three months and includes the standard attestation regarding absence of undisclosed material information.
Kura Oncology (KURA) filed a Form 144 reporting a proposed sale of 8,805 shares of common stock valued at $79,685.25. The shares were acquired as performance stock units (PSUs) on 09/27/2025 and the proposed sale date is 09/29/2025 through Morgan Stanley Smith Barney LLC on the NASDAQ. The filing shows 87,015,518 shares outstanding, and declares no securities sold by the reporting person in the prior three months. The filer certifies they are unaware of undisclosed material adverse information.
Kura Oncology Form 144 notice reporting a proposed sale of 12,314 shares of common stock. The filer intends to sell the shares through Morgan Stanley Smith Barney LLC on NASDAQ around 09/29/2025, with an aggregate market value listed at $111,441.70. The shares were acquired two days earlier on 09/27/2025 as performance stock units (PSUs) issued by the company and are to be paid/settled on 09/29/2025. The filing states there were no other securities sold by the same person in the past three months and includes the standard representation that the seller is not aware of any undisclosed material adverse information about the issuer.
Kura Oncology (KURA) filed a Form 144 reporting a proposed sale of 6,892 shares of common stock through Morgan Stanley Smith Barney LLC on 09/29/2025. The filing lists the aggregate market value of the shares as $62,372.60 and indicates 87,015,518 shares outstanding. The securities were acquired as PSUs from the issuer on 09/27/2025, with payment noted on 09/29/2025. The filer reported no securities sold in the past three months and certified they are unaware of undisclosed material adverse information. Other filer contact fields in the form are present but contain no substantive names or contact details.
Brian T. Powl, Chief Commercial Officer and director at Kura Oncology (KURA), reported receipt of 48,900 shares of common stock from a vesting equity award on 09/27/2025 at no cash price, increasing his beneficial ownership to 108,567 shares. On 09/29/2025 he sold 8,891 shares at $8.9422 per share as a sell-to-cover transaction to satisfy taxes related to the vesting, leaving him with 99,676 shares beneficially owned. The Form 4 was submitted by a single reporting person and includes an attorney-in-fact signature on behalf of the reporting person.
Teresa Brophy Bair, Chief Legal Officer and director of Kura Oncology, reported two transactions tied to performance-based restricted stock units. On September 27, 2025 1/6th of PSUs vested after the company determined that one specified development milestone was met, resulting in the acquisition of 48,900 shares at a $0 price and increasing her beneficial ownership to 156,848 shares. On September 29, 2025 she executed a sell-to-cover tax transaction, selling 8,805 shares at $8.9422 per share, leaving 148,043 shares beneficially owned. The Form 4 was signed by an attorney-in-fact, Thomas Doyle, on September 29, 2025.
Kathleen Ford, Chief Operating Officer of Kura Oncology (KURA), reported the vesting of performance-based restricted stock units after one development milestone was met on 09/27/2025. The filing shows acquisition by vesting of 48,900 shares (price $0) which increased her beneficial ownership to 70,267 shares, followed by a sell-to-cover transaction of 6,892 shares on 09/29/2025 at $8.9422 per share, leaving 63,375 shares beneficially owned. The sale is disclosed as tax withholding related to the vesting of 1/6th of the underlying PSUs from a grant dated 05/31/2023.
Kura Oncology Chief Medical Officer Mollie Leoni received 82,500 shares of common stock upon vesting of performance-based restricted stock units tied to a development milestone achieved on 09/27/2025. Immediately following, 12,314 shares were sold on 09/29/2025 at a price of $8.9422 per share to cover taxes, leaving the reporting person with 158,439 shares beneficially owned. The filing states each PSU converts to one share if performance and service conditions are met; 1/6th of the grant vested when a milestone was met. Transactions were reported on a Form 4 by one reporting person.
Troy E. Wilson, President and CEO and a director of Kura Oncology (KURA), reported the vesting of performance-based restricted stock units and a related sell-to-cover tax sale. On 09/27/2025 182,500 shares were acquired upon the vesting of 1/6th of PSUs granted May 31, 2023 (price reported $0). On 09/29/2025 the reporting person sold 36,615 shares at $8.9422 per share to cover taxes, leaving 246,853 shares held directly. The filing also shows 279,194 shares held indirectly by One Fish Two Fish Revocable Trust and 300,000 shares held indirectly by Lorax Charitable Remainder Unitrust.